http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY#Head http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY http://www.nanopub.org/nschema#hasAssertion http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY#assertion http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY http://www.nanopub.org/nschema#hasProvenance http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY#provenance http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY http://www.nanopub.org/nschema#hasPublicationInfo http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY#pubinfo http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY#assertion http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY#_1 http://purl.obolibrary.org/obo/RO_0002204 http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=3796 http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY#_1 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_36080 http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY#_2 http://purl.obolibrary.org/obo/BFO_0000066 http://disease-ontology.org/term/DOID:2394 http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY#_2 http://purl.obolibrary.org/obo/BFO_0000066 http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=9606 http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY#_2 http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://resource.belframework.org/belframework/20131211/namespace/selventa-legacy-diseases/Cisplatin%20resistance http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY#_2 http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate http://www.selventa.com/vocabulary/increases http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY#_2 http://www.w3.org/1999/02/22-rdf-syntax-ns#subject http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY#_1 http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY#_2 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY#assertion http://www.w3.org/2000/01/rdf-schema#label p(HGNC:FOS) -> path(SDIS:"Cisplatin resistance") http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY#provenance http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel http://purl.org/dc/elements/1.1/description Approximately 61,000 statements. http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel http://purl.org/dc/elements/1.1/rights Copyright (c) 2011-2012, Selventa. All rights reserved. http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel http://purl.org/dc/elements/1.1/title BEL Framework Large Corpus Document http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel http://purl.org/pav/authoredBy http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY#_4 http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel http://purl.org/pav/version 20131211 http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY#_3 http://www.w3.org/ns/prov#value combinations of c-fos antisense and cisplatin reduced the amount of cisplatin required to kill 50% of the C13* cells, although the interaction was not synergistic. These results suggest that expression of the c-fos gene can influence cisplatin sensitivity, and that c-fos antisense oligonucleotide based therapy may be effective at killing parental and cisplatin-resistant ovarian carcinoma cells, either alone or in combination with cisplatin http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY#_3 http://www.w3.org/ns/prov#wasQuotedFrom http://www.ncbi.nlm.nih.gov/pubmed/10644041 http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY#_4 http://www.w3.org/2000/01/rdf-schema#label Selventa http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY#assertion http://www.w3.org/ns/prov#hadPrimarySource http://www.ncbi.nlm.nih.gov/pubmed/10644041 http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY#assertion http://www.w3.org/ns/prov#wasDerivedFrom http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY#assertion http://www.w3.org/ns/prov#wasDerivedFrom http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY#_3 http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY#pubinfo http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY http://purl.org/dc/terms/created 2014-07-03T14:31:33.711+02:00 http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY http://purl.org/pav/createdBy http://orcid.org/0000-0001-6818-334X http://www.tkuhn.ch/bel2nanopub/RAceOh3lk-0CJ8nf7_iEMjPX2VkIvxQd7iZMnBrf80aaY http://purl.org/pav/createdBy http://orcid.org/0000-0002-1267-0234